Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 29, 2016
Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 25, 2014
Details : Undisclosed
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 04, 2014
Lead Product(s) : MGN1703
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703
Details : Undisclosed
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 13, 2013
Lead Product(s) : MGN1703
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MGN1601
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 23, 2010
Lead Product(s) : MGN1601
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 23, 2010
Reset All
